| scholarly article | Q13442814 |
| P819 | ADS bibcode | 1993PNAS...90.8702T |
| P356 | DOI | 10.1073/PNAS.90.18.8702 |
| P932 | PMC publication ID | 47426 |
| P698 | PubMed publication ID | 8378352 |
| P5875 | ResearchGate publication ID | 14821659 |
| P2093 | author name string | Oren M | |
| Shaulian E | |||
| Sigaux F | |||
| Rommelaere J | |||
| Amson R | |||
| Dupressoir T | |||
| Robaye B | |||
| Telerman A | |||
| Tuynder M | |||
| P2860 | cites work | The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias | Q24339375 |
| Mutation and cancer: statistical study of retinoblastoma | Q24618185 | ||
| Parvovirus replication | Q24634739 | ||
| A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma | Q29618817 | ||
| Detection of genes with a potential for suppressing the transformed phenotype associated with activated ras genes | Q33828506 | ||
| Programmed killing of human cells by means of an inducible clone of parvoviral genes encoding non-structural proteins. | Q33921508 | ||
| The p53 proto-oncogene can act as a suppressor of transformation | Q34440370 | ||
| Suppression of Malignancy by Cell Fusion | Q34703177 | ||
| Antineoplasic activity of parvoviruses | Q36935786 | ||
| Flat revertants isolated from Kirsten sarcoma virus-transformed cells are resistant to the action of specific oncogenes | Q37348891 | ||
| Immunologic classification of leukemia and lymphoma | Q39478802 | ||
| The autonomously replicating parvoviruses of vertebrates | Q39657283 | ||
| Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells | Q41407134 | ||
| Permanent conversion of mouse and human cells transformed by activated ras or raf genes to apparently normal cells by treatment with the antibiotic azatyrosine | Q42800528 | ||
| Introduction of a normal human chromosome 11 into a Wilms' tumor cell line controls its tumorigenic expression | Q42820027 | ||
| Melittin resistance: a counterselection for ras transformation | Q42823634 | ||
| Minute virus of mice inhibits cell transformation by simian virus 40 | Q45799432 | ||
| Selective killing of simian virus 40-transformed human fibroblasts by parvovirus H-1. | Q45836799 | ||
| Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. | Q53505779 | ||
| Revertants of v-fos-transformed fibroblasts have mutations in cellular genes essential for transformation by other oncogenes. | Q53526339 | ||
| A sequence in M13 phage detects hypervariable minisatellites in human and animal DNA | Q69893809 | ||
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 5 | |
| P304 | page(s) | 8702-8706 | |
| P577 | publication date | 1993-09-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | A model for tumor suppression using H-1 parvovirus | |
| P478 | volume | 90 |
| Q24630843 | Activation of the human homologue of the Drosophila sina gene in apoptosis and tumor suppression |
| Q33737706 | B1 lymphocytes and myeloid dendritic cells in lymphoid organs are preferential extratumoral sites of parvovirus minute virus of mice prototype strain expression |
| Q24538516 | Biological models and genes of tumor reversion: cellular reprogramming through tpt1/TCTP and SIAH-1 |
| Q35842604 | Conditionally replicative adenovirus for gastrointestinal cancers |
| Q45868174 | Conditionally replicative adenoviruses for cancer therapy |
| Q48589215 | Down-regulation of inwardly rectifying Kir2.1 K+ channels by human parvovirus B19 capsid protein VP1. |
| Q58980225 | Erratum: addendum: Virus-mediated killing of cells that lack p53 activity |
| Q39605370 | Genome replication and postencapsidation functions mapping to the nonstructural gene restrict the host range of a murine parvovirus in human cells |
| Q45869133 | Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer |
| Q47852578 | Inhibition of presenilin 1 expression is promoted by p53 and p21WAF-1 and results in apoptosis and tumor suppression |
| Q44730632 | Interfacial enzymology of parvovirus phospholipases A2. |
| Q47391639 | Introduction: How We Encountered TCTP and Our Purpose in Studying It. |
| Q37290808 | Killing of p53-deficient hepatoma cells by parvovirus H-1 and chemotherapeutics requires promyelocytic leukemia protein |
| Q33713735 | Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: In vitro and in vivo studies |
| Q38061306 | Oncolytic viruses & their specific targeting to tumour cells |
| Q36769180 | Oncolytic viruses in cancer therapy |
| Q33884051 | Parvovirus nonstructural proteins induce an epigenetic modification through histone acetylation in host genes and revert tumor malignancy to benignancy |
| Q39305479 | Phospholipase A2 activity-dependent stimulation of Ca2+ entry by human parvovirus B19 capsid protein VP1 |
| Q42515334 | Potentiation of a recombinant oncolytic parvovirus by expression of Apoptin |
| Q95721053 | Propagation of rat parvovirus in thymic lymphoma cell line C58(NT)d and subsequent appearance of a resistant cell clone after lytic infection |
| Q39631256 | Quantitative Proteomic Analysis of Tumor Reversion in Multiple Myeloma Cells |
| Q28255116 | Reciprocal repression between P53 and TCTP |
| Q35020290 | Replicating parvoviruses that target colon cancer cells |
| Q34297058 | Replication-selective virotherapy for cancer: Biological principles, risk management and future directions |
| Q47160989 | Review: Oncolytic virotherapy, updates and future directions |
| Q47391539 | Role of TCTP for Cellular Differentiation and Cancer Therapy. |
| Q24644076 | SIAH-1 promotes apoptosis and tumor suppression through a network involving the regulation of protein folding, unfolding, and trafficking: identification of common effectors with p53 and p21(Waf1) |
| Q37701517 | Serine protease inhibitor kazal-type 6 inhibits tumorigenesis of human hepatocellular carcinoma cells via its extracellular action |
| Q54479316 | Targeting of autonomous parvoviruses to colon cancer by insertion of Tcf sites in the P4 promoter. |
| Q40663348 | The P4 promoter of the parvovirus minute virus of mice is developmentally regulated in transgenic P4-LacZ mice |
| Q34114807 | The characterization of the human Siah-1 promoter(1). |
| Q37380667 | The molecular programme of tumour reversion: the steps beyond malignant transformation |
| Q35036580 | The p53-Mdm2 module and the ubiquitin system. |
| Q39729356 | Translation control by protein kinase R restricts minute virus of mice infection: role in parvovirus oncolysis. |
| Q28288273 | Translationally controlled tumor protein is a target of tumor reversion |
| Q37028023 | Trial watch: Oncolytic viruses for cancer therapy |
| Q40045867 | Tumor reversion holds promise |
| Q40855415 | Validation and implementation of an internal standard in comet assay analysis |
| Q39770574 | Viral oncolysis that targets Raf-1 signaling control of nuclear transport. |
| Q35795661 | p21WAF-1 reorganizes the nucleus in tumor suppression |
Search more.